Gilead Sciences Inc.

65.95-0.9200-1.38%Vol 7.08M1Y Perf -21.75%
Apr 19th, 2021 16:00 DELAYED
BID65.98 ASK66.00
Open66.70 Previous Close66.87
Pre-Market- After-Market65.95
 - -  - -%
Target Price
76.06 
Analyst Rating
Moderate Buy 2.48
Potential %
15.33 
Finscreener Ranking
★★★     50.76
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.67
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     62.03
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★+     50.60
Market Cap83.03B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
32.26 
Earnings Date
29th Apr 2021

Today's Price Range

65.5967.00

52W Range

56.5685.67

5 Year PE Ratio Range

5.9025.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.63%
1 Month
2.31%
3 Months
-3.00%
6 Months
8.92%
1 Year
-21.75%
3 Years
-10.52%
5 Years
-33.35%
10 Years
225.89%

TickerPriceChg.Chg.%
GILD65.95-0.9200-1.38
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
2.80
3.40
0.50
1.09
5.90
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
79.40
25.50
31.60
46.50
18.18
RevenueValueIndustryS&P 500US Markets
17.03B
13.53
-9.66
-8.37
DividendsValueIndustryS&P 500US Markets
4.31
2.84
9.47
14.59
Payout ratio272.00
Earnings HistoryEstimateReportedSurprise %
Q04 20202.152.191.86
Q03 20201.832.1115.30
Q02 20201.461.11-23.97
Q01 20201.471.6814.29
Q04 20191.581.10-30.38
Q03 20191.661.65-0.60
Q02 20191.681.722.38
Q01 20191.531.679.15
Earnings Per EndEstimateRevision %Trend
3/2021 QR2.0110.44Positive
6/2021 QR1.733.59Positive
12/2021 FY7.233.14Positive
12/2022 FY7.091.43Positive
Next Report Date29th Apr 2021
Estimated EPS Next Report2.00
Estimates Count8
EPS Growth Next 5 Years %12.50
Volume Overview
Volume7.08M
Shares Outstanding1.26B
Trades Count57.24K
Dollar Volume535.12M
Avg. Volume8.40M
Avg. Weekly Volume6.12M
Avg. Monthly Volume6.61M
Avg. Quarterly Volume7.89M

Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 65.95 per share at the end of the most recent trading day (a -1.38% change compared to the prior day closing price) with a volume of 7.20M shares and market capitalization of 83.03B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11800 people. Gilead Sciences Inc. CEO is Daniel O'Day.

The one-year performance of Gilead Sciences Inc. stock is -21.75%, while year-to-date (YTD) performance is 13.2%. GILD stock has a five-year performance of -33.35%. Its 52-week range is between 56.56 and 85.67, which gives GILD stock a 52-week price range ratio of 32.26%

Gilead Sciences Inc. currently has a PE ratio of 743.00, a price-to-book (PB) ratio of 4.63, a price-to-sale (PS) ratio of 4.88, a price to cashflow ratio of 10.30, a PEG ratio of 2.32, a ROA of 8.17%, a ROC of 11.99% and a ROE of 22.76%. The company’s profit margin is 18.18%, its EBITDA margin is 31.60%, and its revenue ttm is $17.03 Billion , which makes it $13.53 revenue per share.

Of the last four earnings reports from Gilead Sciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.00 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Moderate Buy (2.48), with a target price of $76.06, which is +15.33% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gilead Sciences Inc. has a dividend yield of 4.31% with a dividend per share of $2.84 and a payout ratio of 272.00%.

Gilead Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.01, ATR14 : 1.67, CCI20 : 90.90, Chaikin Money Flow : 0.08, MACD : 0.38, Money Flow Index : 45.24, ROC : 2.04, RSI : 54.48, STOCH (14,3) : 61.22, STOCH RSI : 0.49, UO : 55.50, Williams %R : -38.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew Dickinson (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $525 225), Brett A. Pletcher (Sold 26 382 shares of value $1 914 560 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $762 211), Diane E. Wilfong (Sold 12 264 shares of value $982 220 ), Gayle E. Wilson (Option Excercise at a value of $0), Harish Manwani (Option Excercise at a value of $0), Javier J. Rodriguez (Sold 378 shares of value $28 539 ), Johanna Mercier (Option Excercise at a value of $0), John F. Cogan (Option Excercise at a value of $284 321), John F. Cogan (Sold 14 484 shares of value $1 181 171 ), Kevin E. Lofton (Option Excercise at a value of $418 722), Merdad Parsey (Option Excercise at a value of $0), Merdad Parsey (Sold 182 shares of value $12 434 ), Per Wold-Olsen (Option Excercise at a value of $0), Richard J. Whitley (Option Excercise at a value of $0), Sandra J. Horning (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (28.57 %)
6 (27.27 %)
9 (40.91 %)
Moderate Buy
1 (4.76 %)
1 (4.55 %)
2 (9.09 %)
Hold
13 (61.90 %)
13 (59.09 %)
10 (45.45 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.76 %)
2 (9.09 %)
1 (4.55 %)
Summary RatingModerate Buy
2.48
Hold
2.59
Moderate Buy
2.18

Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

CEO: Daniel O'Day

Telephone: +1 650 574-3000

Address: 333 Lakeside Drive, Foster City 94404, CA, US

Number of employees: 11 800

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

50%50%

Bearish Bullish

51%49%

Bearish Bullish

56%44%

News

Stocktwits